Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing

Information

  • Patent Grant
  • 8585683
  • Patent Number
    8,585,683
  • Date Filed
    Monday, March 15, 2010
    14 years ago
  • Date Issued
    Tuesday, November 19, 2013
    11 years ago
Abstract
Assemblies, systems, and methods convey fluid from an internal wound site or body cavity by applying negative pressure from a source outside the internal wound site or body cavity through a wound drain assembly that is placed directly inside the internal wound site or body cavity.
Description
FIELD OF THE INVENTION

This application relates generally to the drainage of fluid from the body during the wound healing process, e.g., following surgery, trauma, or placement of implants or surgical devices.


BACKGROUND OF THE INVENTION

During surgery, or as a result of trauma, tissue volume can be removed or altered, and an open or dead space is created within the tissue that was previously attached to other tissue. The very small blood vessels that previously ran from the underlying tissue (i.e., muscle, connective tissue) to the overlying tissue (i.e., skin, muscle) can be cut or damaged. Although these vessels usually do not cause significant blood loss, they do allow escape of blood serum into the area. Human blood serum contains about ninety-three percent water and about seven percent protein (mostly albumin).


Following surgery or due to trauma, there can also be resulting tissue damage, regardless of how careful the surgeon is. This tissue damage results in cellular death, and the body's natural defense reaction is an inflammatory one. Because of the inflammation, cell death, and increased vascular permeability, fluid can also accumulate in the operative space. The larger the operative space, the greater is the potential for internal fluid collection.


The body can resolve the accumulation of fluid over time, if there is some form of natural drainage, and if there is not continued irritation to the area, and if circulation to the area is sufficient, and if the person is in good health or the volume of fluid collection is itself not too large.


If, for whatever reason, the body is unable to itself efficiently absorb the excess fluid, a seroma can occur. A seroma is defined as a sterile accumulation of blood serum in a circumscribed tissue location or operative space. A seroma is not by definition an “infection;” it does not necessarily involve the presence of white blood cells, bacteria, and the breakdown products of both. A seroma is fluid and blood serum that has accumulated in a dead space in the tissue. A seroma is the result of tissue insult and the product of tissue inflammation and the body's defense mechanisms.


Seromas commonly develop following drain removal or when fluid is produced at a greater rate than it is absorbed. Conventional wound management techniques are commonly applied when a seroma becomes a clinical concern. Placement of a seroma catheter or additional drain, as well as repeated or serial drainage of a seroma, may be required. A seroma or fluid collection is by far the most common complication in surgery today. Such complications result in a significant amount of lost income to patients, as well as expenses to insurers and physicians who have to care for these patients that require serial drainage. Such complications also delay wound healing, may entail additional surgical procedures, and ultimately delay the patient's return to work and routine functional activity. Seroma management can also be costly and, further, can place health care workers to additional needle exposure risks and related outcomes such as hepatitis, etc.


The aim of wound management in both chronic and acute situations is to assist the natural process and prevent further complications such as infection, slough, necrosis formation, and chronic seroma cavities. Maintenance of the optimum wound healing environment is essential, ensuring the wound is kept moist and warm. Wound care products strive to achieve these results and, in turn, help to promote rapid wound closure.


Fluid drainage can be as simple as creating an opening at the lowest edge of the seroma, and keeping this open and clean to allow continued drainage. A clinically accepted way to deal with a seroma that does not appear to be resolving on its own, is to install a continuous drain system, coupled with treatment with antibiotics to prevent infection while the continuous drain system is in use. There are currently numerous types of wound drains on the market, most of them utilizing some form of tubing to withdraw fluid from the wound until the body can resorb the fluid without assistance. A continuous drain system allows the fluid to continuously escape until the body can complete the healing process on its own.


A representative prior art continuous drain system can comprise an implanted device such as a piece of rubber tubing (Penrose drain) (as shown in FIG. 1), which provides dependent gravity drainage or responds to a negative suction force generated by a manual closed suction bulb. These types of drains constitute the most common devices currently available. The problem with these devices is that, although they may drain fluid, fluid drainage is limited to fluid directly around the drain itself. As a result, current drains may manage fluid collection, but they do not effectively clear all of the fluid in the space and, more importantly, they do not clear enough fluid to effectively seal down and close off the dead space.


Another representative prior art continuous drain system, which is currently approved for external use only, can take the form of an externally applied device comprising a piece of foam with an open-cell structure, which coupled to one end of a drain tube (see FIG. 2). The foam is placed externally on top of the wound or skin, and the entire external area is then covered with a transparent adhesive membrane, which is firmly secured to the healthy skin around the wound margin. The opposite end of the drain tube is connected to a vacuum source, and blood or serous fluid are drawn from the wound through the foam into a reservoir for subsequent disposal. Among the numerous names this prior art system is called are “Vacuum Assisted Closure device” or VAC devices. Conventional VAC devices, however, are only approved and used for external wounds only. Conventional VAC devices are not approved or used for internal wounds or operative sites.


Current wound drain devices assemblies at times do not remove a substantial amount of fluid from within a wound and have other performance issues. For example, external VAC devices clear fluid directly around external wounds (as FIG. 3 shows), and they are limited to the application to external wounds only. They leave the remainder of the wound site or operating space open and filled with fluid.


Furthermore, the clinical use of external VAC devices may not make wound drainage more cost-effective, clinician-friendly, and patient-friendly.


For example, the foam structures and adhesive membranes associated with conventional practices of external VAC need to be periodically removed and replaced. Currently, dressing changes are recommended every 48 hours for adults with non-infected wounds, and daily for infants and adolescents. Current techniques place the foam material in direct contact with granulating tissue. Removal of the foam structures in the presence of granulating tissue and the force of pressure on the wound bed that this removal can cause pain or discomfort. The sponge can also break into particulates and remain in the wound. Furthermore, the multiple steps of the conventional external VAC procedure—removing the adhesive membrane, then removing the old foam structures, then inserting the new foam structures, and then reapplying the adhesive member along the entire periphery of the wound—are exacting, tedious and time consuming. They only prolong pain or discomfort, and cause further disruption to the patient, and also demand dedicated nursing time and resources.


Furthermore, to function correctly, the adhesive membrane applied over the foam wound structures must form an airtight seal with the skin. Obtaining such a seal can be difficult, particularly in body regions where the surrounding skin is tortuous, and/or mucosal and/or moist.


Furthermore, prolonged wearing of wet dressings can cause further breakdown and maceration of the surrounding skin thereby increasing the wound size. This can cause further discomfort to the patient, and the exudate can often be offensive in odor and color causing further embarrassment to the patient. This may, in turn, require more numerous dressing changes and re-padding throughout the day, which is disruptive to the patient and costly both in terms of nursing time and resources.


Furthermore, since the membrane and the material of the foam structures are both in direct contact with tissue, tissue reactions can occur.


There remains a need for improved drains, systems, devices, methods that are cost-effective, patient-friendly, and clinician-friendly.


SUMMARY OF THE INVENTION

The invention provides assemblies, systems, and methods that are cost-effective, patient-friendly, and clinician-friendly. The assemblies, systems, and methods convey fluid from an internal wound site or body cavity by applying negative pressure from a source that is outside the internal wound site or body cavity through a wound drain assembly that is placed directly inside the internal wound site or body cavity. Unlike conventional VAC devices, the assemblies, systems, and methods that embody the technical features of the invention are not a treatment modality that is limited to placement on an exterior wound or operational site following trauma or surgery, providing drainage in a reactive and localized fashion. Instead, the assemblies, systems, and methods that embody the technical features of the invention make possible a treatment modality that is sized and configured for placement directly inside an internal wound site or body cavity at the time of surgery, to provide direct and immediate drainage of any entire wound site in a proactive fashion.


One aspect of the invention provides a wound drain assembly comprising a housing enclosing an open interior. The housing is sized and configured for placement directly within an interior wound site or body cavity. Perforations in the housing communicate with the open interior. A foam sponge material is carried within the open interior. The foam sponge material absorbs fluid residing in the interior wound site or body cavity. Tubing is coupled to the housing in communication with the open interior of the housing. The tubing extends from within the interior wound site to outside the interior wound site or body cavity. The tubing outside the interior wound site or body cavity is sized and configured to be coupled to a source of negative pressure outside the body cavity. The negative pressure conveys through the tubing fluid that is absorbed by the foam sponge material inside the internal wound site or body cavity.


Another aspect of the invention provides a wound drain system comprising a wound drain assembly as just described, which is coupled to a source of negative pressure outside the body cavity.


Another aspect of the invention provides a wound drain assembly comprising a wound drainage structure comprising a material capable of being absorbed by the body. The wound drainage structure is sized and configured to absorb fluid in an interior wound site or body cavity. According to this aspect of the invention, tubing is releasably coupled to the wound drainage structure. The tubing extends outside the interior wound site or body cavity to be coupled to a source of negative pressure outside the body cavity to convey fluid absorbed by the material from the internal wound site or body cavity. After conveying the desired volume of fluid from the body, the tubing can be disconnected from the wound drainage structure, to allow the wound drainage structure to be absorbed by the body.


Other aspects of the invention provide methods that provide the wound drain assembly or system as above described and that operate the assembly or system to convey fluid from an interior wound site or body cavity.


The assembly, system, and/or method apply a vacuum of significant pressure internally and directly in a wound area or body cavity for enhanced wound healing benefits. By applying a vacuum of significant consistent pressure internally and directly in the wound area or body cavity, the assembly, system, and/or method reduce the “dead-space” or open area inside the wound or cavity, and thereby aid in decreasing tissue edema and swelling of the overlying and underlying tissue. The assembly, system, and/or method increase the nature and extent of wound drainage, promote tissue adherence and closure of wounds, and thus decrease seroma formation and promote primary wound healing. The assembly, system, and/or method thereby decrease the costly and increased patient morbidity caused by seroma formation and the resultant delay in primary wound healing or need for additional surgical procedures or drainage.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is an anatomic side section prior art view of a human abdomen showing an interior wound area and a tube that is placed according to conventional techniques to drain fluid from a seroma at the wound site.



FIG. 2 is an anatomic side section prior art view of an exterior wound area showing an external VAC device placed according to conventional techniques to drain fluid from a seroma only at an external wound site.



FIG. 3 is an anatomic, somewhat diagrammatic prior art view of the limited drainage area achieved by the external VAC device shown in FIG. 2.



FIG. 4 is an anatomic side section view of a human abdomen, like that shown in FIG. 1, but showing a drain system that embodies features of the invention, comprising an internally placed wound drain assembly coupled to an external source of negative pressure.



FIG. 5 is an anatomic, somewhat diagrammatic view of the enhanced drainage area achieved by the drain system shown in FIG. 4.



FIG. 6 is a perspective, exploded view of a representative embodiment of a wound drain assembly of the type shown in FIG. 4.



FIGS. 7A and 7B are enlarged views of representative forms of foam sponge material that the wound drain assembly shown in FIG. 6 carries.



FIG. 8 is a perspective, assembled view of the wound drain assembly shown in FIG. 6.



FIGS. 9 to 13 are perspective views of other representative embodiments of a wound drain assembly of the type shown in FIG. 4.



FIGS. 14 and 15 are representative views of various systems of a type shown in FIG. 4.



FIGS. 16 and 17 show, respectively, a wound drain assembly of the type shown in FIG. 4 before and during the application of negative pressure.



FIG. 18 shows, in an anatomic view, a system like that shown in FIG. 4, comprising a wound drain assembly coupled to a portable source of negative pressure that can be carried by an individual, but also be fixed or attached to a wall section.



FIGS. 19A, 19B, and 19C show, in an anatomic view, s system like that shown in FIG. 4, comprising an absorbable would drain assembly.





DESCRIPTION OF THE PREFERRED EMBODIMENT

Although the disclosure hereof is detailed and exact to enable those skilled in the art to practice the invention, the physical embodiments herein disclosed merely exemplify the invention that may be embodied in other specific structure. While the preferred embodiment has been described, the details may be changed without departing from the invention, which is defined by the claims.



FIG. 4 shows a wound drainage system 10 comprising an internal drain assembly 12 that is sized and configured for surgical placement within a wound area W (or body cavity). The wound area W may be anywhere in a human or animal, e.g., within a body cavity, or beneath the skin, or in muscle, or within the soft tissues. As will be described in greater detail later (see FIG. 6), the internal drain assembly 12 includes a housing 18 that encloses a foam sponge component 16. The foam sponge component 16 communicates with the wound area W through one or more apertures 20 formed in the housing 18.


The internal drain assembly 12 is coupled to drain tubing 14, which is desirable flexible. The drain tubing 14 extends outside the wound area W. The drain tubing 14 can extend through a percutaneous incision in the skin overlying any wound area W. Alternatively, the drain tubing 14 can extend through an opening in a skin flap bounding the wound area. The flexible drain tubing 14 includes a terminal end 22 that extends outside the body.


The terminal end 22 desirably includes a quick release connector 24. The connector 24 is sized and configured to be connected to a conventional external negative pressure suction device 26 (such as a V.A.C.® device made by KCI International, or a conventional wall suction or other regulated vacuum device).


In use, the drain tubing 14 is connected to the suction device 26, and the suction device 26 is operated to apply a requisite negative pressure through the internal drain assembly 12. Blood or serous fluid absorbed by and passing through the foam sponge component 16 are drawn by the negative pressure from the wound area W. The drain tubing 14 desirably includes an inline reservoir 30 to collect the withdrawn fluid for disposal.


As FIG. 5 shows, occupying the interior of the wound area W, the internal drain assembly 12 conveys negative pressure throughout the entire open volume of the wound space. The negative pressure applied by the internal drain assembly 12 clears fluid from the entire wound volume. The removal of fluid from the entire wound volume promotes tissue adherence within the wound space, to close the wound space and seal the wound.


As FIGS. 4 and 5 show, the drain tubing 14 desirably includes an inline one-way backflow valve V. The one-way backflow valve V allows fluid to be drawn from the wound volume into the reservoir 30. Upon disconnection of the drain tubing 14 from the external negative pressure suction device 26 (via the connector 24), the one-way backflow valve V prevents air or fluid to flow backward into the wound or body. The one-way backflow valve V keeps the internal drain assembly 12 closed when not connected to the external negative pressure suction device 26.


As FIGS. 6 and 8 show, the internal drain assembly 12 comprises a housing 18. The housing 18 is made from an inert, biocompatible material that does not adhere to or activate the body's natural foreign body defense mechanism. The material can comprise, e.g., silicone rubber, polyurethane, or other biocompatible plastics.


The housing 18 can be formed. e.g., by extrusion, molding, or machining. As will be described in greater detail later, the housing 18 can be formed in various shapes and sizes, depending upon the requirements and morphology of the wound site and function and use of the drain. In the configuration shown in FIG. 8, a representative size measures about 5″ (length)×about ¾″ (width)×about ½″ (height).


The housing 18 is formed to include a hollow interior chamber 28, which is enclosed by the side and end walls of the housing 18. The housing 18 is also formed to include one or more through-slots, through-apertures, or through-perforations 20 in the side and/or end walls of the housing 18. The through-slots, through-holes, or through-perforations 20 open the hollow interior chamber 28 to communication with the wound site environment outside the housing 18.


An end of the flexible drain tubing 14 is coupled to the housing 18 and opens into the hollow interior chamber 28. The flexible drain tubing 14 is made of medical grade, inert material. e.g., silicone rubber, polyurethane, or other biocompatible plastics. The tubing is desirably sized and configured to accommodate sufficient fluid flow with a relatively small and tolerable incision size (e.g., about 2-3″ in diameter).


A foam sponge component 16 is housed within the hollow interior chamber 28. The foam sponge component 16 is characterized in that it does not break into particulates in the presence of fluid and pressure. The foam sponge material can comprise, e.g., an open-cell porous structure (see FIG. 7A) or a granulated foam construction (see FIG. 7B). The foam sponge component 16 can be variously constructed from a biocompatible material that does not adhere to or activate the body's natural foreign body defense mechanism, e.g., sponge materials used with conventional VAC devices. As stated later, the foam sponge component 16 can be impregnated with antibacterial products or solutions, or other hormone or natural or manmade stimulating factors that can decrease the chance of infection and/or accelerate wound healing.


In use (as FIGS. 4 and 5 show), the internal drain assembly 12 is placed within an interior of the wound area W (or body cavity). Fluids collecting in the wound or body cavity are absorbed by and pass through the foam sponge component 16 through the perforations 20 in the housing 18. Fluid absorbed by the foam sponge component is siphoned away by the drain tubing 14 when a requisite negative pressure is applied.


The negative pressure can be, e.g., 125 to 200 mmHg, and is desirably about 125 mmHg, below ambient pressure. The amount of negative vacuum pressure can, be regulated in a continuous, discontinuous, or otherwise variable manner, to maximize wound healing and closure and thereby reduce overlying soft tissue edema and swelling. In this way, the system 10 promotes primary wound healing while also decreasing or minimizing seroma formation.


As FIGS. 16 and 17 show, the introduction of negative pressure into the housing 18 can cause the housing 18 to collapse against the foam sponge component 16 (as FIG. 17 shows), while the through-perforations 20 of the housing 18 maintain open paths for fluid to be absorbed by the foam sponge component 16.


The foam sponge component 16 is desirably compressible for easy insertion into and removal from the housing 18 for replacement. The configuration of the housing 18 can also provide a contour that facilitates sliding of the internal drain assembly 12, easing removal from the body.


The foam sponge component 16 may also be impregnated with components such as silver or antibacterials or other growth factors that may decrease infection and promote wound healing.


The foam sponge component may also include other hormone or natural or manmade stimulating factors that can decrease the chance of infection and/or accelerate wound healing.


As FIGS. 9 to 13 show, the housing 18 can be formed in various dimensions, shapes, and sizes, and the foam sponge component 16 cut to corresponding dimensions, shapes, and sizes. These dimensions, shapes, and sizes can comprise, e.g., square (FIG. 9); oval (FIG. 10); hexagonal (FIG. 11); round (FIG. 12); or rectangular (FIG. 13); or any linear or curvilinear shape or combinations thereof. The ends of the housing 18 can be tapered or not tapered (as FIGS. 9 to 13 demonstrate). The through-perforations 20 can also be variously shaped and sized (as FIGS. 9 to 13 demonstrate). The through-perforations 20 can also be tapered or not tapered along their axes.


The wound drainage system 10 can be variously configured and assembled. For example, as shown in FIG. 14, the in-line reservoir 30 is intended, in use, to be placed at a gravity position at or below the drain assembly 12 and includes separate fluid inlet and vacuum outlet paths arranged along the top of the reservoir 20, coupled, respectively, to the internal drain assembly 12 and the external negative pressure suction device 26. As FIG. 15 shows, the reservoir 30 is intended, in use, to be placed at a gravity position above the drain assembly 12 and includes an fluid inlet path arranged along the bottom of the reservoir 30 (coupled to the drain assembly 12) and a vacuum outlet port arranged along the top of the reservoir 30 (coupled to the external negative pressure suction device 26).


As FIG. 18, the system 10 may include a battery powered external negative pressure suction device 26′ that can be carried by the individual. The system 10 can therefore be operated while the individual ambulates, so that the individual need not be bed-bound during the recovery period.


As shown in FIG. 19A, the internal drain assembly 12 can comprise an absorbable mesh structure 40 coupled to the tubing 12. The absorbable mesh structure 40 can be made of sterile material, such as, e.g., Vicryl, moncryl, PDS or other absorbable material that could be woven into a foam-like construct. In this embodiment, when the internal drain assembly 12 has completed its job (see FIG. 19B), the silicone or plastic tubing 14 is detached from mesh structure 40 and removed, leaving the absorbable mesh structure 40 inside the body, to dissolve and absorb just like absorbable suture, as shown in FIG. 19C.


It is believed that applying a vacuum of significant pressure internally and directly in a wound area or body cavity removes chronic edema and leads to increased localized blood flow. It is also believed that the applied forces applied internally and directly in a wound area result in the enhanced formation of tissue adherence. It is further believed that applying a vacuum of significant pressure internally and directly in a wound area or body cavity will accelerate healing by the application of a universal negative force to the entire wound volume, drawing the wound edges together, assisting closure, enhancing wound healing, and decreasing dead space and seroma. Presumed mechanisms responsible for achieving these objectives include: (i) changes in microvascular blood flow dynamic; (ii) changes in interstitial fluid; (iii) removal of wound exudates; (iv) stimulation of growth factors and collagen formation; (iv) reduction in bacterial colonization; (v) mechanical closure of wound by “reverse tissue expansion;” (vi) increasing adherence of the soft tissue and internal wound healing; and (vii) decreasing dead space and seroma formation.


The foregoing is considered as illustrative only of the principles of the invention. Furthermore, since numerous modifications and changes will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and operation shown and described. While the preferred embodiment has been described, the details may be changed without departing from the invention, which is defined by the claims.

Claims
  • 1. A method comprising creating percutaneous access into a wound of an individual defined by an interior dead space having a volume enclosed between interior tissue surfaces consisting of muscle, connective, or skin tissue containing blood vessels that have been separated by surgery or trauma within a body beneath substantially intact skin, and in which extracellular blood and serous fluid escaping from the blood vessels can accumulate to form a seroma,providing a wound closure device comprising a wound drainage structure sized and configured for placement entirely within the interior dead space, the wound drainage structure comprising a perforated housing, the wound closure device comprising tubing coupled to the wound drainage structure, the tubing sized and configured to be coupled to a source of negative pressure outside the body to convey negative pressure for application internally into the interior dead space,placing the wound drainage structure within the interior dead space,extending the tubing from the interior dead space through the percutaneous access to a location outside the body,coupling the tubing to a source of negative pressure outside the body,operating the source of negative pressure to convey negative pressure at a negative pressure at 125 to 200 mmHg below ambient pressure into the wound closure device for application internally into the interior dead space, andin response to the applied negative pressure, conveying extracellular blood and serous fluid from the interior dead space through the perforated housing to draw together the separated interior tissue surfaces to promote adherence of the tissue surfaces, closure of the dead space during a wound healing process.
  • 2. A method according to claim 1wherein the tubing includes a connector for releasable connection to the source of negative pressure outside the body.
  • 3. A method according to claim 1further including collecting the extracellular blood and serous fluid in a reservoir communicating with the tubing outside the body.
  • 4. A method according to claim 1wherein the tubing is flexible.
  • 5. A method according to claim 1wherein the tubing conveys negative pressure through one or more apertures for application internally into the interior dead space.
  • 6. A method according to claim 1wherein the wound drainage structure comprises a material communicating with the tubing to take in the extracellular blood serous fluid from the interior dead space.
  • 7. A method according to claim 6wherein the material does not break into particulates in the presence of fluid and pressure.
  • 8. A method according to claim 6wherein the material is capable of being absorbed by the body,further including, after drawing together the separated interior tissue surfaces to promote adherence of the tissue surfaces, closure of the dead space, during the wound healing process, separating the tubing from material, removing the tubing from the open interior, and allowing the material to be absorbed by the body.
  • 9. A method according to claim 6wherein the material comprises an open cell material.
  • 10. A method according to claim 6wherein the material comprises a foam sponge material.
  • 11. A method according to claim 1wherein operating the source of negative pressure includes regulating the negative pressure in a continuous manner.
  • 12. A method according to claim 1wherein operating the source of negative pressure includes regulating the negative pressure in a variable manner.
  • 13. A method according to claim 1wherein the source of negative pressure is portable.
  • 14. A method according to claim 1wherein the source of negative pressure can be carried by the individual.
  • 15. A method comprising creating percutaneous access into a wound of an individual defined by an interior dead space having a volume enclosed between interior tissue surfaces consisting of muscle, connective, or skin tissue containing blood vessels that have been separated by surgery or trauma within a body beneath substantially intact skin, and in which extracellular blood and serous fluid escaping from the blood vessels can accumulate to form a seroma,providing a portable source of negative pressure that is battery powered and can be carried by the individual,providing a wound drainage structure comprising tubing having a proximal region sized and configured to be coupled to the portable source of negative pressure outside the body and a distal region having a perforated housing sized and configured to extend from the source of negative pressure through a percutaneous access in the substantially intact skin to a location within the interior dead space to convey negative pressure for application internally into the interior dead space,coupling the proximal region of the tubing to the portable source of negative pressure outside the body,placing the distal region of the tubing through a percutaneous access in the substantially intact skin in a location within the interior dead space to convey negative pressure for application internally into the interior dead space,operating the portable source of negative pressure at a negative pressure at 125 to 200 mmHg below ambient pressure while the individual ambulates and carries the portable source of negative pressure, thereby conveying extracorporeal blood and serous fluid through the perforated housing into the tubing from the interior dead space and draw the separated interior tissue surfaces together to promote adherence of the tissue surfaces and closure of the dead space.
  • 16. A method according to claim 15wherein the tubing includes a connector for releasable connection to the portable source of negative pressure outside the body.
  • 17. A method according to claim 15further including collecting the extracellular blood and serous fluid in a reservoir communicating with the tubing outside the body.
  • 18. A method according to claim 15wherein the tubing is flexible.
  • 19. A method according to claim 15wherein the tubing conveys negative pressure through one or more apertures for application internally into the interior dead space.
  • 20. A method according to claim 15wherein the wound drainage structure comprises a material communicating with the tubing to take in the extracellular blood and serous fluid from the interior dead space.
  • 21. A method according to claim 20wherein the material does not break into particulates in the presence of fluid and pressure.
  • 22. A method according to claim 20wherein the material is capable of being absorbed by the body,further including, after drawing together the separated interior tissue surfaces to promote adherence of the tissue surfaces, closure of the dead space, during a wound healing process, separating the tubing from material, removing the tubing from the open interior, and allowing the material to be absorbed by the body.
  • 23. A method according to claim 20wherein the material comprises an open cell material.
  • 24. A method according to claim 20wherein the material comprises a foam sponge material.
  • 25. A method according to claim 15wherein operating the source of negative pressure includes regulating the negative pressure in a continuous manner.
  • 26. A method according to claim 15wherein operating the source of negative pressure includes regulating the negative pressure in a variable manner.
RELATED APPLICATION

This application is a continuation of application Ser. No. 11/810,027 filed 4 Jun. 2007 now U.S. Pat. No. 7,699,831, which is a continuation-in-part of application Ser. No. 11/646,918, filed Dec. 28, 2006 and entitled Assemblies, Systems, and Methods for Vacuum Assisted Internal Drainage During Wound Healing, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/810,733, filed Jun. 2, 2006, and entitled “Foam Sponge Vacuum Assisted Internal Drainage System,” which are each incorporated herein by reference.

US Referenced Citations (232)
Number Name Date Kind
1355846 Rannells Oct 1920 A
2547758 Keeling Apr 1951 A
2632443 Lesher Mar 1953 A
2682873 Evans et al. Jul 1954 A
2969057 Simmons Jan 1961 A
3066672 Crosby, Jr. et al. Dec 1962 A
3367332 Groves Feb 1968 A
3394702 Heimlich et al. Jul 1968 A
3520300 Flower, Jr. Jul 1970 A
3556101 Economou Jan 1971 A
3568675 Harvey Mar 1971 A
3589368 Jackson Jun 1971 A
3595241 Sheridan Jul 1971 A
3648692 Wheeler Mar 1972 A
3682180 McFarlane Aug 1972 A
3826254 Mellor Jul 1974 A
3830238 Kurtz et al. Aug 1974 A
3935863 Kliger Feb 1976 A
3957054 McFarlane May 1976 A
4080970 Miller Mar 1978 A
4096853 Weigand Jun 1978 A
4139004 Gonzalez, Jr. Feb 1979 A
4165748 Johnson Aug 1979 A
4184510 Murry et al. Jan 1980 A
4217904 Zahorsky Aug 1980 A
4233969 Lock et al. Nov 1980 A
4245630 Lloyd et al. Jan 1981 A
4250882 Adair Feb 1981 A
4256109 Nichols Mar 1981 A
4257422 Duncan Mar 1981 A
4261363 Russo Apr 1981 A
4275721 Olson Jun 1981 A
4284079 Adair Aug 1981 A
4294240 Thill Oct 1981 A
4297995 Golub Nov 1981 A
4317452 Russo et al. Mar 1982 A
4333468 Geist Jun 1982 A
4341212 Medwid Jul 1982 A
4346711 Agdanowski et al. Aug 1982 A
4373519 Errede et al. Feb 1983 A
4382441 Svedman May 1983 A
4392853 Muto Jul 1983 A
4392858 George et al. Jul 1983 A
4398910 Blake et al. Aug 1983 A
4419097 Rowland Dec 1983 A
4430084 Deaton Feb 1984 A
4432853 Banks Feb 1984 A
4445897 Ekbladh et al. May 1984 A
4465485 Kashmer et al. Aug 1984 A
4475909 Eisenberg Oct 1984 A
4480638 Schmid Nov 1984 A
4523920 Russo Jun 1985 A
4525166 Leclerc Jun 1985 A
4525374 Vaillancourt Jun 1985 A
4533356 Bengmark et al. Aug 1985 A
4540412 Van Overloop Sep 1985 A
4543100 Brodsky Sep 1985 A
4548202 Duncan Oct 1985 A
4551139 Plaas et al. Nov 1985 A
4553966 Korteweg Nov 1985 A
4569348 Hasslinger Feb 1986 A
4579555 Russo Apr 1986 A
4605399 Weston et al. Aug 1986 A
4608041 Nielsen Aug 1986 A
4633865 Hengstberger et al. Jan 1987 A
4640688 Hauser Feb 1987 A
D288962 Blake Mar 1987 S
4655754 Richmond et al. Apr 1987 A
4664662 Webster May 1987 A
4692153 Berlin et al. Sep 1987 A
4710165 McNeil et al. Dec 1987 A
4717379 Elkholwe Jan 1988 A
4728642 Pawelchak et al. Mar 1988 A
4733659 Edenbaum et al. Mar 1988 A
4743232 Kruger May 1988 A
4758220 Sundblom et al. Jul 1988 A
4787888 Fox Nov 1988 A
4815468 Annand Mar 1989 A
4825866 Pierce May 1989 A
4826494 Richmond et al. May 1989 A
4838883 Matsuura Jun 1989 A
4840187 Brazier Jun 1989 A
4844072 French et al. Jul 1989 A
4863449 Therriault et al. Sep 1989 A
4872450 Austad Oct 1989 A
4878901 Sachse Nov 1989 A
4897081 Poirier et al. Jan 1990 A
4899965 Usui Feb 1990 A
4906233 Moriuchi et al. Mar 1990 A
4906240 Reed et al. Mar 1990 A
4908350 Kramer et al. Mar 1990 A
4919654 Kalt et al. Apr 1990 A
4925452 Melinyshyn et al. May 1990 A
4941882 Ward et al. Jul 1990 A
4953565 Tachibana et al. Sep 1990 A
4969880 Zamierowski Nov 1990 A
4985019 Michelson Jan 1991 A
5037397 Kalt et al. Aug 1991 A
5045075 Ersek Sep 1991 A
5053021 Feibus Oct 1991 A
5085633 Hanifl et al. Feb 1992 A
5086170 Luheshi et al. Feb 1992 A
5092858 Benson et al. Mar 1992 A
5100395 Rosenberg Mar 1992 A
5100396 Zamierowski Mar 1992 A
5116310 Seder et al. May 1992 A
5134994 Say Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5167613 Karami et al. Dec 1992 A
5176663 Svedman et al. Jan 1993 A
5180375 Feibus Jan 1993 A
5192266 Wilk Mar 1993 A
5215522 Page et al. Jun 1993 A
5232453 Plass et al. Aug 1993 A
5261893 Zamierowski Nov 1993 A
5278100 Doan et al. Jan 1994 A
5279550 Habib et al. Jan 1994 A
5298015 Komatsuzaki et al. Mar 1994 A
5342376 Ruff Aug 1994 A
5344415 DeBusk et al. Sep 1994 A
5358492 Feibus Oct 1994 A
5358494 Svedman Oct 1994 A
5360414 Yarger Nov 1994 A
5437622 Carion Aug 1995 A
5437651 Todd et al. Aug 1995 A
5437683 Neumann et al. Aug 1995 A
5441481 Mishra et al. Aug 1995 A
5443848 Kramer et al. Aug 1995 A
5451204 Yoon Sep 1995 A
5466231 Cercone et al. Nov 1995 A
5484399 Diresta et al. Jan 1996 A
5484428 Drainvill et al. Jan 1996 A
5527293 Zamierowski Jun 1996 A
5549579 Batdorf et al. Aug 1996 A
5549584 Gross Aug 1996 A
5554138 Stanford et al. Sep 1996 A
5556375 Ewall Sep 1996 A
5599330 Rainin Feb 1997 A
5607388 Ewall Mar 1997 A
5628735 Skow May 1997 A
5636643 Argenta et al. Jun 1997 A
5637103 Kerwin et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5662598 Tobin Sep 1997 A
5678564 Lawrence et al. Oct 1997 A
5701917 Khouri Dec 1997 A
5792173 Breen et al. Aug 1998 A
5891111 Ismael Apr 1999 A
5893368 Sugerman Apr 1999 A
5902260 Gilman et al. May 1999 A
5911222 Lawrence et al. Jun 1999 A
5921972 Skow Jul 1999 A
5938626 Sugerman Aug 1999 A
5947953 Ash et al. Sep 1999 A
6042539 Harper et al. Mar 2000 A
6051747 Lindqvist et al. Apr 2000 A
6071267 Zamierowski Jun 2000 A
6099513 Spehalski Aug 2000 A
6135116 Vogel et al. Oct 2000 A
6174306 Fleischmann Jan 2001 B1
6190349 Ash et al. Feb 2001 B1
6235009 Skow May 2001 B1
6241747 Ruff Jun 2001 B1
6264979 Svedman Jul 2001 B1
6287316 Agarwal et al. Sep 2001 B1
6290685 Insley et al. Sep 2001 B1
6345623 Heaton et al. Feb 2002 B1
6383162 Sugarbaker May 2002 B1
6458109 Henley et al. Oct 2002 B1
6478789 Spehalski et al. Nov 2002 B1
6488643 Tumey et al. Dec 2002 B1
6493568 Bell et al. Dec 2002 B1
6537241 Odland Mar 2003 B1
6553998 Heaton et al. Apr 2003 B2
6565544 Rainin May 2003 B1
6605068 Righetti Aug 2003 B2
6626891 Ohmstede Sep 2003 B2
6685681 Lockwood et al. Feb 2004 B2
6695823 Line et al. Feb 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6814079 Heaton et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6866657 Shchervinsky Mar 2005 B2
6913589 Dextradeur et al. Jul 2005 B2
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
6979324 Bybordi et al. Dec 2005 B2
7004915 Boynton et al. Feb 2006 B2
7105001 Mandelbaum Sep 2006 B2
7182758 McCraw Feb 2007 B2
7195624 Lockwood et al. Mar 2007 B2
7276051 Henley et al. Oct 2007 B1
7322971 Shehada Jan 2008 B2
7338482 Lockwood et al. Mar 2008 B2
7381859 Hunt et al. Jun 2008 B2
7413571 Zamierowski Aug 2008 B2
7476205 Erdmann Jan 2009 B2
7658735 Spehalski Feb 2010 B2
7717871 Odland May 2010 B2
7918817 Schon et al. Apr 2011 B2
20010029956 Argenta Oct 2001 A1
20010043943 Coffey Nov 2001 A1
20020062097 Simpson May 2002 A1
20020065494 Lockwood et al. May 2002 A1
20020077661 Saadat Jun 2002 A1
20020115951 Norstrem et al. Aug 2002 A1
20020115956 Ross Aug 2002 A1
20020120185 Johnson Aug 2002 A1
20020128578 Johnston et al. Sep 2002 A1
20020143286 Tumey Oct 2002 A1
20020161317 Risk et al. Oct 2002 A1
20030109855 Solem et al. Jun 2003 A1
20030208149 Coffey Nov 2003 A1
20040260230 Randolph Dec 2004 A1
20050004536 Opie et al. Jan 2005 A1
20050085795 Lockwood Apr 2005 A1
20050101922 Anderson et al. May 2005 A1
20050131327 Lockwood et al. Jun 2005 A1
20050137539 Biggie et al. Jun 2005 A1
20050148963 Brennan Jul 2005 A1
20050261642 Weston Nov 2005 A1
20050273066 Wittmann Dec 2005 A1
20060015087 Risk et al. Jan 2006 A1
20060029650 Coffey Feb 2006 A1
20060041247 Petrosenko et al. Feb 2006 A1
20060079852 Bubb Apr 2006 A1
20060189910 Johnson et al. Aug 2006 A1
20070027414 Hoffman et al. Feb 2007 A1
20080058684 Ugander et al. Mar 2008 A1
20080167593 Fleischmann Jul 2008 A1
20090099519 Kaplan Apr 2009 A1
20100030132 Niezgoda et al. Feb 2010 A1
Foreign Referenced Citations (77)
Number Date Country
550575 Aug 1982 AU
755496 Feb 2002 AU
2005436 Jun 1990 CA
2 303 085 Mar 1999 CA
26 40 413 Mar 1978 DE
2754775 Jun 1979 DE
43 06 478 Sep 1994 DE
295 04 378 Oct 1995 DE
20115990 Dec 2001 DE
69806842 Jan 2003 DE
60118546 Aug 2006 DE
102006032870 Jan 2008 DE
0100148 Feb 1984 EP
0117632 Sep 1984 EP
0161865 Nov 1985 EP
271491 Jun 1988 EP
0358302 Mar 1990 EP
0506992 Oct 1992 EP
0555293 Aug 1993 EP
0777504 Jun 1997 EP
0 853 950 Oct 2002 EP
1284777 Feb 2003 EP
1 088 569 Aug 2003 EP
1018967 Aug 2004 EP
0 688 189 Jun 2005 EP
0 620 720 Nov 2006 EP
692578 Jun 1953 GB
2058227 Apr 1981 GB
2 195 255 Apr 1988 GB
2 197 789 Jun 1988 GB
2 220 357 Jan 1990 GB
2 235 877 Mar 1991 GB
2329127 Mar 1999 GB
2 333 965 Aug 1999 GB
2342584 Apr 2000 GB
2 329 127 Aug 2000 GB
2365350 Feb 2002 GB
3056429 May 1991 JP
H3-56429 May 1991 JP
4129536 Apr 1992 JP
71559 Apr 2002 SG
WO 8002182 Oct 1980 WO
WO 8701027 Feb 1987 WO
WO 8704626 Aug 1987 WO
WO 9010424 Sep 1990 WO
WO 9207519 May 1992 WO
WO 9309727 May 1993 WO
WO 9420041 Sep 1994 WO
WO 9605873 Feb 1996 WO
WO 9634636 Nov 1996 WO
WO 9718007 May 1997 WO
WO-9901173 Jan 1999 WO
WO 9913793 Mar 1999 WO
WO 0007653 Feb 2000 WO
WO 0007653 Feb 2000 WO
WO 0042958 Jul 2000 WO
WO 0057794 Oct 2000 WO
WO 0059418 Oct 2000 WO
WO 0059424 Oct 2000 WO
WO 0134223 May 2001 WO
WO 0171231 Sep 2001 WO
WO0185248 Nov 2001 WO
WO 0185248 Nov 2001 WO
WO 0189431 Nov 2001 WO
WO 03057307 Jul 2003 WO
WO 03086232 Oct 2003 WO
WO2004041346 May 2004 WO
WO 2006048246 May 2006 WO
WO 2007031762 Mar 2007 WO
WO 2007041642 Apr 2007 WO
WO 2007109209 Sep 2007 WO
WO 2007133618 Nov 2007 WO
WO 2008014358 Jan 2008 WO
WO 2008040020 Apr 2008 WO
WO 2008041926 Apr 2008 WO
WO 2008103625 Aug 2008 WO
WO 2012080783 Jun 2012 WO
Non-Patent Literature Citations (111)
Entry
US 6,216,701, 04/2001, Heaton (withdrawn)
Product description Endo Sponge, www.bbraun.com, Jun. 18, 2008.
Mees et al., “Endo-Vacuum Assisted Closure Treatment for Rectal Anastomotic Insufficiency”, Diseases of Colon and Rectum, vol. 51: 404-410,2008.
Cholmondeley Williams et al., “The Effect of Hematoma on the Thickness of Pseudosheaths Around Silicone Implants”, presented at the Am Soc of Plastic and Reconstructure Surgeons, Houston, TX, Oct. 30, 1974.
Shermak, Michele A et al., “Seroma Development Following Body Contouring Surgery for Massive Weight Loss: Patient Risk Factors and Treatment Strategies”, Division of Plastic Surgery and the Department of Surgery, the Johns Hopkins Medical Inst5itutions, pp. 280-288; Jul. 12, 2007.
Saxena et al., “Vacuum-Assisted Closure: Microdeformations of Wounds and Cell Proliferation”, Plastic and Reconstructive Surgery, J vol. 115, No. 5, pp. 1086-1096, Oct. 2004.
Response filed Oct. 4, 2010 for U.S. Appl. No. 12/466,973.
Advisory Action date mailed Oct. 12, 2010 for U.S. Appl. No. 12/466,973.
RCE/Response filed Nov. 2, 2010 for U.S. Appl. No. 12/466,973.
N.A. Badautdihov, “Variant of External . . . ”, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986);pp. 94-96.
Louis C. Argenta, MD and Michael J. Morykwas, PhD; “Vacuum-Assisted Closure: A New Method for Wound . . . ”: Annals of Plastic Surgery, vol. 38, No. 6, Jun. 1997; pp. 563-576.
Susan Mendez-Eastmen, RN; “When Wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24.
James H. Blackburn, II, MD, et al., “Negative-Pressure Dressings as a Bolster for Skin Grafts”; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457.
John Masters; “Reliable . . . ”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/British Assocn of Plastic Surgeons, UK.
S.E. Greer, et al, “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of . . . ”, British Journal of Plastic Suraery (2000), 53, pp. 484-487.
George V. Letsou, MD., et al.; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells . . . ”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639.
Orringer, Jay, et al. “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80.
International Search Report for PCT International Application PCT/GB95/01983; Nov. 23, 1995.
PCT International Search Report for PCT International Application PCT/GB98/02713; Jan. 8, 1999.
PCT Written Opionion; PCT International Application PCT/GB98/02713; Jun. 8, 1999.
PCT International Examination and Search Report; PCT International Application PCT/GB96/02802; Jan. 15, 1998 & Apr. 29, 1997.
PCT Written Opinion, PCT International Application PCT/GB96/02802; Sep. 3, 1997.
Dattilo, Philip, P., Jr., et al., “Medical Textiles: Application of an . . . ”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5.
Kostyuchenok, B.M., et al., “Vacuum Treatment in the Surgical Managment of . . . ”, Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof.
Davydov, Yu. A., et al., “Vacuum Therapy in the Treatment of Purulent Lactation . . . ”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof.
Yusupov, Yu, N. et al., “Active Wound Drainage”, Vestnik Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof.
Davydov, Yu. A. et al., “Bacteriological and Cytological Assessment of Vacuum Therapy for . . . ”; Vestnik Khirurgi, Oct. 1988, pp. 48-52, and 8 page English translation thereof.
Davydov, Yu. A. et al, Concepts for the Clinical-Biological Management of the Wound . . . ; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof.
Chariker, Mark E. M.D., et al., “Effective Management of Incisional and Cutaneous Fistulae with Closed Suction . . . ”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63.
Egnell Minor, “Instruction Book”, First Edition, 300 7502, Feb. 1975, pp. 24.
Egnell Minor, “Addition to the Users Manual Concerning Overflow Protection—Concerns All Egnell Pumps”, Feb. 3, 1983, pp. 2.
Svedman, P., “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534.
Chinn, Steven D. et al., “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 4, No. 1, 1985, pp. 76-81.
Arnljots, Bjorn et al., “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable . . . ”, Scand J. Plastic Reconstr. Surgery, No. 19, 1985, pp. 211-213.
Svedman, P., “A Dressing Allowing Continuous Treatment . . . ”, IRCS Medical Science: Biomedical Technoloay, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221.
Svedman, P. et al., “A Dressing System Providing Fluid Supply and Suction Drainage Used for . . . ”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133.
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing . . . ”, Chronic Wound Care, edited by D. Krasner (Health Managment Publications, Inc., King of Prussia, PA 1990), pp. 240-246.
G. Zivadinovic, V. Dukic, Z. Maksimovic, D. Radak, and P. Peska, “Vacuum Therapy in the . . . ”, Timok Medical Journal 11 (1986), pp. 161-164.
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain”, Surgery, Gynecology, and Obstetrics 159 (1984), pp, 584-585.
A.A. Safronov, Dissertation Abstract . . . , (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967).
M. Schein, R. Saadia, J.R. Jamieson, and G.A G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen”, British Journal of Surgery 73 (1936), pp. 369-370.
D.E. Tribble, “An improved Sump Drain-Irrigation Device of Simple Construction”, Archives of Surgery 105 (1972), pp. 511-513.
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method . . . ”, Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I).
C. E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremeties . . . ”, Journal of the American Medical Association 64 (1915), pp. 1548-1549.
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in . . . , (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211.
The V.A.C.™ Vacuum Assisted Closure, Assisting in Wound Closure, Brochure, Jan. 1996, 5 pages, 1-A-042, KCI®, San Antonio, Texas.
Argenta et al., “The V.A.C.™, Case Study #4”, Case Study, Mar. 1995, 1 page, 35-D-004, KCI®, San Antonio, Texas.
Argenta et al., “The V.A.C.™, Case Study #3”, Case Study, Mar. 1995, 1 page, 35-D-003, KCI®, San Antonio, Texas.
“The V.A.C.® Operations Summary, the V.A.C.® Wound Closure System Applications”, Brochure, Mar. 1997, 4 pages, 1-A-060, KCI®, San Antonio, Texas.
“The V.A.C.® Operations Summary, The V.A.C.® Wound Closure System Applications”, Brochure, Mar. 1999, 2 pages, 1-A-060, KCI®, San Antonio, Texas.
Argenta et al., “V.A.C.® Wound Closure Device Case Study #3”, Case Study, Apr. 1998, 1 page, 35-D-003, KCI®, San Antonio, Texas.
Argenta et al., “V.A.C.® Wound Closure Device Case Study #1”, Case Study, Apr. 1998, 1 page, 35-D-001, KCI®, San Antonio, Texas.
Argenta et al., “V.A.C.® Wound Closure Device Case Study #8”, Case Study, Jun. 1996, 2 pages, 35-D-008, KCI®, San Antonio, Texas.
Argenta et al., “V.A.C.® Wound Closure Device Case Study #7”, Case Study, Jun. 1996, 2 pages, 35-D-007, KCI®, San Antonio, Texas.
Argenta et al., “V.A.C.® Wound Closure Device Case Study #6”, Case Study, Jun. 1996, 2 pages, 35-D-006, KCI®, San Antonio, Texas.
Argenta et al., “V.A.C.® Wound Closure Device Case Study #9”, Case Study, Jun. 1996, 2 pages, 35-D-009, KCI®, San Antonio, Texas.
Argenta et al., “V.A.C.® Wound Closure Device Case Study #5”. Case Study, Aug. 1994, 2 pages, 35-D-005, KCI®, San Antonio, Texas.
Argenta et al., “V.A.C.® Wound Closure Device Case Study #4”, Case Study, Aug. 1994, 2 pages, 35-D-004, KCI®, San Antonio, Texas.
Argenta et al., “V.A.C.® Wound Closure Device Case Study #3”, Case Study, Aug. 1994, 2 pages, 35-D-003, KCI®, San Antonio, Texas.
Argenta et al., “V.A.C.® Wound Closure Device Case Study #2”, Case Study, Aug. 1994, 2 pages, 35-D-002, KCI®, San Antonio, Texas.
Argenta et al., “V.A.C.® Wound Closure Device Case Study #1”, Case Study, Aug. 1994, 2 pages, 35-D-001, KCI®, San Antonio, Texas.
Ex parte Quayle Office Action dated Feb. 7, 2005 for U.S. Appl. No. 10/275,671.
Amendment filed Apr. 8, 2005 to Office Action dated Feb. 7, 2005 for U.S. Appl. No. 10/275,671.
Non-Final Office Action dated Jun. 27, 2005 for U.S. Appl. No. 10/275,671.
Response filed Oct. 19, 2005 to Non-Final Office Action dated Jun. 27, 2005 for U.S. Appl. No. 10/275,671.
Non-Final Office Action dated Jan. 10, 2006 for U.S. Appl. No. 10/275,671.
Response filed Jul. 10, 2006 to Non-Final Office Action dated Jan. 10, 2006 for U.S. Appl. No. 10/275,671.
Supplemental Amendment filed Aug. 10, 2006 for U.S. Appl. No. 10/275,671.
Final Office Action dated Apr. 17, 2007 for U.S. Appl. No. 10/275,671.
Response filed Jun. 12, 2007 to Final Office Action dated Apr. 17, 2007 for U.S. Appl. No. 10/275,671.
Advisory Action dated Jul. 11, 2007 for U.S. Appl. No. 10/275,671.
Response filed Aug. 17, 2007 to Advisory Action dated Jul. 11, 2007 for U.S. Appl. No. 10/275,671.
Non-Finai Office Action dated Sep. 5, 2007 for U.S. Appl. No. 10/275,671.
Response filed Sep. 5, 2007 to Non-Final Office Action dated Sep. 5, 2007 for U.S. Appl. No. 10/275,671.
Notice of Allowance and Fee(s) Due dated Feb. 4, 2008 for U.S. Appl. No. 10/275,671.
V.A. Solovev et al., “Guidelines, The Method . . . ”, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovey Guidelines”.
V.A. Kuznetsov & N.A. Bagautdinov, “Vacuum and Vacuum-Sorption . . . ”, edited by B.M, Kostyuchenok et al, (Moscow, U.S.S.R. Oct. 28-29, 1936) pp. 91-92 (“Bagautdinov II”).
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures . . . , (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”).
Notice of Allowance date mailed Feb. 4, 2008 for U.S. Appl. No. 10/275,671.
Translation of the Nullity Action of Sep. 10, 2010 (submitted by applicant).
Meyer et al., “A New Abdominal Drain for Overflowing Lavage in Instances of Severe Pancreatitis with Persistent . . . ”, Surg. Gynecol. Obstet. Sep. 1987: 165 (3): 271-3.
Poritz, “Percutaneous Drainage and Ileocolectomy for Spontaneous Intraabdominal Abscess in Chrohns Disease . . . ”, J, Gastrointest. Surg. Feb. 2007: 11 (2):204-0.
Khurrum et al., “Percutaneous Postoperative Intra-abdominal Abscess Drainage After Elective Colorectal Surgery . . . ”, Tech. Coloprotocl. Dec. 2002: 6(3): 159-64.
Reckard et al., “Management of Intraabdominal . . . ”, Journal of Vascual Interventional Journal of Vascual Interventional Radiology, vol. 16, Issue 7, pp. 1019-1021.
Latenser et al., “A Pilot Study Comparing Percutaneous Decompression with Decompressive Laparotomy for Acute . . . ”, J Burn Care & Rehav, 23(3): 190-195.
Kubiak et al., “Reduced Intra-Peritoneal Inflammation . . . ”, Critical Care I, vol. 207, No. 3S, Sep 2008, S34-35.
Kaplan, “Managing the Open Abdomen”; Ostomy Wound Management, Jan. 2004; 50 1A supply; C2; 1-8.
Kaplan et al., “Guidelines for the Management of the Open Abdomen”, Wounds Oct. 2005; 17 (Suppl 1); S1S24.
Garner et al., “Vacuum-assisted Wound Closure Provides Early Fascial Reapproximation . . . ”, The American Journal of Surgery, Dec. 2001; 182 (6); 630-8.
Barker et al., “Vacuum Pack of Technique of Temporary Abdominal Closure: A 7-year Experience with 112 Patients . . . ”, J Trauma Feb. 1, 2000; 48 (2): 201-6.
Brock et al., “Temporary Closure of Open Abdominal Wounds: The Vacuum Pack”, Am Surg. Jan. 1995, 61 (1): 30-5.
Sherck et al., “Covering the ‘Open Abdomen’: A Better Technique”, Am Surg. Sep. 1998: 64(9): 854-7.
Dubick et al., “Issues of Concern Regarding the Use of Hypertonic/Hyperoncotic Fluid Resuscitation of Hemorrhagic Hypotension . . . ”, Apr. 2006; 25 (4); 321-8.
Burdette, “Systemic Inflammatory Response Syndrome”, http://emedicine.medscape.com/article/168943-print, Apr. 2007.
Beamis Hydrophobic Rigid Canisters—http://www.bemishealthcare.com/docs/Canister Hydrophobic.pdf (date unknown).
Fink et al., “Textbook of Critical Care”, 5th ed. (Philadelphia: Elsevier, 2005), 1933-1943.
International Search Report and Written Opinion date mailed Nov. 5, 2009 for PCT/US2009/044264.
International Search Report and Written Opinion date mailed Nov. 18, 2009 for PCT/US2009/044230.
International Search Report and Written Opinion date mailed Sep. 17, 2009 for PCT/US2009/044240.
International Search Report and Written Opinion date mailed Nov. 5, 2009 for PCT/US2009/044268.
International Search Report and Written Opinion date mailed Oct. 6, 2009 for PCT/US2009/044226.
International Search Report and Written Opinion date mailed Oct. 15, 2009 for PCT/US2009/044244.
International Search Report and Written Opinion date mailed Oct. 6, 2009 for PCT/US2009/044266.
International Search Report and Written Opinion date mailed Nov. 5, 2009 for PCT/US2009/044245.
International Search Report and Written Opinion date mailed Oct. 23, 2009 for PCT/US2009/044235.
Restriction Requirement date mailed Jan. 4, 2010 for U.S. Appl. No. 12/466,973.
Response filed Jan. 21, 2010 for U.S. Appl. No. 12/466,973.
Non-Final Office Action date mailed Mar. 5, 2010 for U.S. Appl. No. 12/466,973.
Response filed May 20, 2010 for U.S. Appl. No. 12/466,973.
Examiner Interview Summary date mailed May 25, 2010 for U.S. Appl. No. 12/466,973.
Final Office Action date mailed Aug. 12, 2010 for U.S. Appl. No. 12/466,973.
Related Publications (1)
Number Date Country
20100179516 A1 Jul 2010 US
Provisional Applications (1)
Number Date Country
60810733 Jun 2006 US
Continuations (1)
Number Date Country
Parent 11810027 Jun 2007 US
Child 12661293 US
Continuation in Parts (1)
Number Date Country
Parent 11646918 Dec 2006 US
Child 11810027 US